Jennifer M Zupancic
Overview
Explore the profile of Jennifer M Zupancic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han Y, Desai A, Zupancic J, Smith M, Tessier P, Ruotolo B
Protein Sci
. 2024 May;
33(6):e5008.
PMID: 38723181
One of the most important attributes of anti-amyloid antibodies is their selective binding to oligomeric and amyloid aggregates. However, current methods of examining the binding specificities of anti-amyloid β (Aβ)...
2.
McArthur N, Kang B, Moctezuma F, Shaikh A, Loeffler K, Bhatt N, et al.
Biotechnol Prog
. 2024 Apr;
40(5):e3463.
PMID: 38568030
Alzheimer's disease and other tauopathies are characterized by the misfolding and aggregation of the tau protein into oligomeric and fibrillar structures. Antibodies against tau play an increasingly important role in...
3.
Pornnoppadol G, Bond L, Lucas M, Zupancic J, Kuo Y, Zhang B, et al.
Cell Chem Biol
. 2023 Oct;
31(2):361-372.e8.
PMID: 37890480
The inability of antibodies to penetrate the blood-brain barrier (BBB) is a key limitation to their use in diverse applications. One promising strategy is to deliver IgGs using a bispecific...
4.
Makowski E, Wang T, Zupancic J, Huang J, Wu L, Schardt J, et al.
Nat Biomed Eng
. 2023 Sep;
8(1):45-56.
PMID: 37666923
Antibody development, delivery, and efficacy are influenced by antibody-antigen affinity interactions, off-target interactions that reduce antibody bioavailability and pharmacokinetics, and repulsive self-interactions that increase the stability of concentrated antibody formulations...
5.
Zupancic J, Smith M, Trzeciakiewicz H, Skinner M, Ferris S, Makowski E, et al.
Front Immunol
. 2023 Aug;
14:1164080.
PMID: 37622125
Single-domain antibodies, also known as nanobodies, are broadly important for studying the structure and conformational states of several classes of proteins, including membrane proteins, enzymes, and amyloidogenic proteins. Conformational nanobodies...
6.
Desai A, Zupancic J, Trzeciakiewicz H, Gerson J, DuBois K, Skinner M, et al.
bioRxiv
. 2023 Jul;
PMID: 37461643
Antibodies that recognize specific protein conformational states are broadly important for research, diagnostic and therapeutic applications, yet they are difficult to generate in a predictable and systematic manner using either...
7.
Pornnoppadol G, Bond L, Lucas M, Zupancic J, Kuo Y, Zhang B, et al.
bioRxiv
. 2023 May;
PMID: 37162883
The inability of antibodies and other biologics to penetrate the blood-brain barrier (BBB) is a key limitation to their use in diagnostic, imaging, and therapeutic applications. One promising strategy is...
8.
Makowski E, Chen H, Lambert M, Bennett E, Eschmann N, Zhang Y, et al.
MAbs
. 2022 Nov;
14(1):2146629.
PMID: 36433737
Self-association governs the viscosity and solubility of therapeutic antibodies in high-concentration formulations used for subcutaneous delivery, yet it is difficult to reliably identify candidates with low self-association during antibody discovery...
9.
Makowski E, Kinnunen P, Huang J, Wu L, Smith M, Wang T, et al.
Nat Commun
. 2022 Jul;
13(1):3788.
PMID: 35778381
Therapeutic antibody development requires selection and engineering of molecules with high affinity and other drug-like biophysical properties. Co-optimization of multiple antibody properties remains a difficult and time-consuming process that impedes...
10.
Desai A, Zupancic J, Smith M, Tessier P
Methods Mol Biol
. 2022 Apr;
2491:471-490.
PMID: 35482203
Conformational antibodies specific for amyloid-forming peptides and proteins are important for a range of biomedical applications, including detecting, inhibiting, and potentially treating protein aggregation disorders ranging from Alzheimer's to Parkinson's...